U.S. markets open in 8 hours 20 minutes
  • S&P Futures

    3,634.00
    +1.25 (+0.03%)
     
  • Dow Futures

    29,979.00
    -19.00 (-0.06%)
     
  • Nasdaq Futures

    12,112.00
    +36.00 (+0.30%)
     
  • Russell 2000 Futures

    1,852.00
    +0.50 (+0.03%)
     
  • Crude Oil

    45.10
    +0.19 (+0.42%)
     
  • Gold

    1,801.40
    -3.20 (-0.18%)
     
  • Silver

    23.17
    -0.13 (-0.58%)
     
  • EUR/USD

    1.1903
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    0.8820
    0.0000 (0.00%)
     
  • Vix

    21.64
    -1.02 (-4.50%)
     
  • GBP/USD

    1.3349
    -0.0009 (-0.07%)
     
  • USD/JPY

    104.4810
    +0.0010 (+0.00%)
     
  • BTC-USD

    18,854.80
    -213.69 (-1.12%)
     
  • CMC Crypto 200

    373.80
    +4.05 (+1.10%)
     
  • FTSE 100

    6,432.17
    +98.33 (+1.55%)
     
  • Nikkei 225

    26,369.71
    +204.12 (+0.78%)
     

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

Editas Medicine, Inc.
·2 min read

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly appointed Executive Vice President and Chief Medical Officer, Lisa Michaels, M.D. In connection with Dr. Michaels’ appointment, the Editas Medicine Board of Directors approved a stock option grant and a restricted stock unit award to Dr. Michaels as inducements material to Dr. Michaels entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option provides for the purchase of up to 120,000 shares of Editas Medicine common stock at a price of $30.41 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Dr. Michaels’ employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Dr. Michaels’ continued service relationship with Editas Medicine through the applicable vesting dates. The restricted stock unit award is for 20,000 shares of Editas Medicine common stock and vests as to 25 percent of the shares on each one-year anniversary of Dr. Michaels’ employment start date until the fourth anniversary of Dr. Michaels’ employment start date, subject to Dr. Michaels’ continued service to Editas Medicine through the applicable vesting dates.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

CONTACT: Contacts: Media Cristi Barnett (617) 401-0113 cristi.barnett@editasmed.com Investors Mark Mullikin (617) 401-9083 mark.mullikin@editasmed.com